Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
12:05pm, Wednesday, 01'st Apr 2026
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results
09:20am, Wednesday, 01'st Apr 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported mixed phase three trial data for efzimfotase alfa, its treatment for hypophosphatasia, a rare genetic disease that impairs the body's ability to mine
New Era Energy & Digital announces planned joint venture for West Texas data center
06:20am, Wednesday, 01'st Apr 2026
New Era Energy & Digital (NASDAQ:NUAI) announced that it has signed a non-binding letter of intent to form a joint venture aimed at developing and financing...
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
06:19am, Wednesday, 01'st Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel...
Graphene Manufacturing Group receives industry certification and quality audit approval
06:15am, Wednesday, 01'st Apr 2026
Graphene Manufacturing Group Ltd (TSX-V:GMG, OTCQX:GMGMF) announced that it has been certified as a Verified Graphene Producer by the Advanced Carbons...
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
08:23am, Tuesday, 31'st Mar 2026
The company said the results support the drug's potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.
Lilly's $2 Billion AI Deal Raises Stakes
08:04am, Tuesday, 31'st Mar 2026
Eli Lilly (LLY) has signed a deal worth up to $2 billion with Hong Kong-listed Insilico Medicine for exclusive rights to develop and sell a GLP-1 diabetes drug
Astrazeneca Plc $AZN Shares Bought by Allspring Global Investments Holdings LLC
03:22am, Tuesday, 31'st Mar 2026
Allspring Global Investments Holdings LLC lifted its position in shares of Astrazeneca Plc (NYSE: AZN) by 750.5% during the undefined quarter, according to the company in its most recent filing with t
Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients
10:17am, Monday, 30'th Mar 2026
Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), arriving at a moment when the market had all but written off the drug's pr
Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings
09:58am, Monday, 30'th Mar 2026
AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year.
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
09:45am, Monday, 30'th Mar 2026
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options.
AA Financial Advisors LLC Has $557,000 Stake in Astrazeneca Plc $AZN
03:04am, Monday, 30'th Mar 2026
AA Financial Advisors LLC lowered its position in shares of Astrazeneca Plc (NYSE: AZN) by 31.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Com
Chesley Taft & Associates LLC Acquires 25,985 Shares of Astrazeneca Plc $AZN
04:33am, Sunday, 29'th Mar 2026
Chesley Taft and Associates LLC increased its holdings in shares of Astrazeneca Plc (NYSE: AZN) by 20.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 152,
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
07:15pm, Friday, 27'th Mar 2026
In the latest trading session, Astrazeneca (AZN) closed at $188.42, marking a +2.74% move from the previous day.
International ETFs: EEM and IEFA Offer Distinct Global ETF Choices
10:08am, Friday, 27'th Mar 2026
Expense, risk, and sector focus set these two ETFs apart-see which aligns better with your global investing strategy.
